Essilor : Disclosure of Share Capital and Voting Rights Outstanding as of
September 30, 2013
(Pursuant to Article L.233-8 II of the French Commercial Code and articles
221-1 and 223-16 of the General Regulations of the Autorité des Marchés
CHARENTON-LE-PONT, France -- October 3, 2013
Regulatory News :
As of September 30, 2013, shares and voting rights outstanding of Essilor
(Paris:EI), the world leader in ophthalmic optics, broke down as follows:
September 30, 2013
Shares outstanding 215,693,967
Exercisable voting rights 225,825,515
Total voting rights, based on all outstanding shares, 231,696,519
including shares stripped of their voting rights*
(*) Shares held by the Company, either in treasury or under the liquidity
The world’s leading ophthalmic optics company, Essilor designs, manufactures
and markets a wide range of lenses to improve and protect eyesight. Its
corporate mission is to enable everyone around the world to access lenses that
meet his or her unique vision requirements. To support this mission, the
Company allocates more than €150 million to research and innovation every
year, in a commitment to continuously bring new, more effective products to
market. Essilor’s flagship brands are Varilux^®, Crizal^®, Definity^®,
Xperio^®, Optifog^TM and Foster Grant^®. It also develops and markets
equipment, instruments and services for eyecare professionals.
Essilor reported consolidated revenue of approximately €5 billion in 2012 and
employs around 50,700 people in some 100 countries. It operates 22 plants,
more than 400 prescription laboratories and edging facilities, as well as
several research and development centers around the world.
For more information, please visit www.essilor.com.
The Essilor share trades on the NYSE Euronext Paris market and is included in
the Euro Stoxx 50 and CAC 40 indices.
Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.
Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16
Press spacebar to pause and continue. Press esc to stop.